S
Sebastian Kreil
Researcher at Heidelberg University
Publications - 59
Citations - 3544
Sebastian Kreil is an academic researcher from Heidelberg University. The author has contributed to research in topics: Transplantation & Imatinib mesylate. The author has an hindex of 19, co-authored 50 publications receiving 3357 citations. Previous affiliations of Sebastian Kreil include University of Mannheim & Salisbury District Hospital.
Papers
More filters
Journal ArticleDOI
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Andreas Hochhaus,Sebastian Kreil,Amie S. Corbin,P La Rosée,P La Rosée,Martin C. Müller,T. Lahaye,Benjamin Hanfstein,Claudia Schoch,Nicholas C.P. Cross,Ute Berger,Harald Gschaidmeier,Brian J. Druker,Ruediger Hehlmann +13 more
TL;DR: Although the heterogeneous development of imatinib resistance is challenging, the fact that BCR-ABL is active in many resistant patients suggests that the chimeric oncoprotein remains a good therapeutic target.
Journal ArticleDOI
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Amy V. Jones,Sebastian Kreil,Katerina Zoi,Katherine Waghorn,Claire Curtis,Lingyan Zhang,Joannah Score,Rachel Seear,Andrew Chase,Francis H. Grand,Helen E. White,Christine Zoi,Dimitris Loukopoulos,Evangelos Terpos,Elisavet-Christine Vervessou,Beate Schultheis,Michael Emig,Thomas Ernst,Eva Lengfelder,Rüdiger Hehlmann,Andreas Hochhaus,David Oscier,Richard T. Silver,Andreas Reiter,Nicholas C.P. Cross +24 more
TL;DR: It is concluded that V617F is widespread in MPDs and detection of this acquired mutation is likely to have a major impact on the way patients with MPD are diagnosed, as well as serving as an obvious target for signal transduction therapy.
Journal ArticleDOI
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.
Francis H. Grand,Claire Hidalgo-Curtis,Thomas Ernst,Katerina Zoi,Christine Zoi,Carolann McGuire,Sebastian Kreil,Amy V. Jones,Joannah Score,Georgia Metzgeroth,David Oscier,Andrew J. Hall,Christian Brandts,Hubert Serve,Andreas Reiter,Andrew Chase,Nicholas C.P. Cross +16 more
TL;DR: It is concluded that acquired, transforming CBL mutations are a novel and widespread pathogenetic abnormality in morphologically related, clinically aggressive MPNs.
Journal ArticleDOI
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Kirsten Merx,Martin C. Müller,Sebastian Kreil,T. Lahaye,Peter Paschka,Claudia Schoch,A. Weisser,Christian Kuhn,Ute Berger,Harald Gschaidmeier,Ruediger Hehlmann,Andreas Hochhaus +11 more
TL;DR: In this paper, a real-time RT-PCR approach using fluorescent-labeled hybridization probes (LightCycler technology) was used to determine whether BCR-ABL transcript levels can predict chromosomal response.
Journal ArticleDOI
Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis
Celalettin Ustun,Andreas Reiter,Bart L. Scott,Ryotaro Nakamura,Gandhi Damaj,Sebastian Kreil,Ryan Shanley,William J. Hogan,Miguel-Angel Perales,Tsiporah B. Shore,Herrad Baurmann,Robert K. Stuart,Bernd Gruhn,Michael Doubek,Jack W. Hsu,Eleni Tholouli,Tanja Gromke,Lucy A. Godley,Livio Pagano,Andrew L. Gilman,Eva Wagner,Tor Shwayder,Martin Bornhäuser,Esperanza B. Papadopoulos,Alexandra Böhm,Gregory M. Vercellotti,Maria Teresa Van Lint,Christoph Schmid,Werner Rabitsch,Vinod Pullarkat,Faezeh Legrand,Ibrahim Yakoub-Agha,Wael Saber,John Barrett,Olivier Hermine,Hans Hägglund,Wolfgang R. Sperr,Uday R. Popat,Edwin P. Alyea,Steven M. Devine,H. Joachim Deeg,Daniel J. Weisdorf,Cem Akin,Peter Valent +43 more
TL;DR: AlloHCT was associated with long-term survival in patients with advanced SM, and may be considered as a viable and potentially curative therapeutic option for advanced SM in the meantime.